



TRIMURTHI
GROUP

20th August, 2020

To
The General Manager,
Department of Corporate Relations,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai -400001.

Dear Sir,

Scrip Code: 536565

Sub: Outcome of Board Meeting dated 20th August, 2020 and Disclosure as per Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

We wish to inform you that at the meeting of the Board of Directors of the Company held today i.e. on Thursday, 20th August, 2020, the Board of Directors of the Company have inter-alia considered, approved and took on record the unaudited standalone and consolidated financial results of the Company for the quarter ended 30th June, 2020. The said unaudited financial results were reviewed by the Audit Committee and thereafter approved by the Board of Directors.

The Statutory Auditors have carried out a "Limited Review" of the unaudited Financial Results for the quarter ended 30th June, 2020.

In compliance with Regulations 33 & Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of the Standalone and Consolidated Financial Results and Limited Review Report of the Statutory Auditors of the Company.

The Board Meeting commenced at 11:00 a.m. and concluded at 3:00 P.M.

This is for your information and records.

Thanking you.

Yours faithfully,

For Trimurthi Limited

(Arun Kumar Bhangadia)
Managing Director
DIN: 00021024



Encl: As above

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956



TRIMURTHI
GROUP

TRIMURTHI LIMITED
64-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095.
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS
FOR THE QUARTER I ENDED 30TH JUNE 2020

(Amount in lakhs except EPS)

PARTICULARS	QUARTER ENDED			YEAR ENDED 31.03.2020 (AUDITED)
	30.06.2020 (UNAUDITED)	31.03.2020 (AUDITED)	30.06.2019 (UNAUDITED)	
1. INCOME				
INCOME FROM OPERATIONS	24.10	51.05	31.77	103.23
OTHER INCOME	11.72	10.41	4.09	47.31
TOTAL INCOME	35.32	61.44	35.86	150.54
2. EXPENSES				
PURCHASES	28.83	24.81	17.10	73.21
COST OF MATERIALS CONSUMED				
MANUFACTURING EXPENSES				
WORK IN PROGRESS AND STOCK IN TRADE	(2.40)	(1.13)	(1.86)	2.44
RENT	0.20	1.05	-	1.95
EMPLOYEE BENEFITS EXPENSE	6.28	6.90	5.49	28.30
FINANCE COSTS	-	-	-	-
DEPRECIATION AND AMORTISATION EXPENSES	2.18	0.92	2.57	7.82
OTHER EXPENSES	6.71	9.24	8.67	26.16
TOTAL EXPENSES	63.80	41.79	32.08	139.69
3. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE EXCEPTIONAL ITEMS (1-2)	(6.48)	19.65	3.78	10.65
4. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS				
5. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (3-4)	(6.48)	19.65	3.78	10.65
6. TAX EXPENSES				
CURRENT TAX	(0.07)	1.31	1.07	1.17
TAX ADJUSTMENTS RELATING TO EARLIER YEARS	-	0.64	1.10	0.64
DEFERRED TAX (NET)	(0.07)	0.47	(0.02)	0.55
7. NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (5-6)	(6.41)	18.55	2.71	9.48
8. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS				
9. TAX EXPENSES FOR DISCONTINUED OPERATIONS				
10. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (8-9)				
11. PROFIT/(LOSS) FOR THE PERIOD (7+10)	(6.41)	18.55	2.71	9.48
12. OTHER COMPREHENSIVE INCOME				
A. (i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS				
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS				
B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS				
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS	0.11	(2.01)	(0.90)	(3.43)
13. TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12) (COMPRISING PROFIT (LOSS) AND OTHER COMPREHENSIVE INCOME)	(6.30)	16.54	0.81	6.05
14. EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATION)				
(i) BASIC	(0.08)	0.23	0.03	0.12
(ii) DILUTED	(0.08)	0.23	0.03	0.12
15. EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATION) :				
(i) BASIC				
(ii) DILUTED				
16. EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATIONS) :				
(i) BASIC	(0.08)	0.23	0.03	0.12
(ii) DILUTED	(0.08)	0.23	0.03	0.12

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)



TRIMURTHI
GROUP

PARTICULARS	QUARTER ENDED			YEAR ENDED 31.03.2020 (AUDITED)
	30.06.2020 (UNAUDITED)	31.03.2020 (AUDITED)	30.06.2019 (UNAUDITED)	
PARTICULARS OF SHARE HOLDING				
Public Share Holding				
- Number of Shares	2900600	2900600	2900600	2900600
- Percentage of shareholding	35.81%	35.81%	35.81%	35.81%
Promoters and promoter group shareholding				
a. Pledged / encumbered				
- No of equity Shares	-NIL-	-NIL-	-NIL-	-NIL-
- Percentage of Shares (of the shareholding of promoter and promoter	-NIL-	-NIL-	-NIL-	-NIL-
- Percentage of Shares (of the total share capital of the company)	-NIL-	-NIL-	-NIL-	-NIL-
b. Non encumbered				
- No of Equity Shares	5199400	5199400	5199400	5199400
- Percentage of Shares (of the shareholding of promoter and promoter	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.19%	64.19%	64.19%	64.19%

Particulars	3 Months Ended (30/06/2020)
Investor Complaints	
Pending at the beginning of the quarter	-NIL-
Received during the quarter	-NIL-
Disposed during the quarter	-NIL-
Remaining unsolved during the quarter	-NIL-

PARTICULARS	QUARTER ENDED			YEAR ENDED 31.03.2020 (AUDITED)
	30.06.2020 (UNAUDITED)	31.03.2020 (AUDITED)	30.06.2019 (UNAUDITED)	
Segment Revenue				
a. Pharma Business	-	-	-	-
b. Financial Services	7.44	10.67	12.88	42.56
c. Investments	3.78	(0.48)	3.85	4.53
d. Trading in Shares	24.10	31.25	19.13	103.45
e. Foods	-	-	-	-
	35.32	61.44	35.86	150.54
-NIL-	-NIL-	-NIL-	-NIL-	-NIL-
	35.32	61.44	35.86	150.54
Segment Profits (Before tax & Interest from Each Segment)				
a. Pharma Business	-	-	-	-
b. Financial Services	7.44	10.57	6.18	42.56
c. Investments	3.78	(0.48)	3.85	4.53
d. Trading in Shares	(17.70)	9.46	(6.25)	(36.44)
e. Foods	-	-	-	-
	(6.48)	19.63	3.78	10.65
f. Interest	-NIL-	-NIL-	-	-
g. Other Un-allocable expenses net off	-NIL-	-NIL-	-NIL-	-NIL-
h. Un-allocable Income	-NIL-	-NIL-	-NIL-	-NIL-
	(6.48)	19.63	3.78	10.65
Capital Employed				
a. Pharma Business	29.50	29.50	-	29.50
b. Financial Services	267.00	367.98	301.39	367.98
c. Investments	33.61	23.18	26.74	23.18
d. Trading in Shares	390.66	466.44	377.29	496.64
e. Foods	300.00	300.00	13.85	300.00
Total	1,200.80	1,287.10	1,291.86	1,207.10

Notes:

Previous period figures have been regnated, wherever necessary, for the purpose of comparison.

The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 20-06-2020.

The above standee financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34- Interim Financial Reporting prescribed under Section 133 of the Companies Act,2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.

For Trimurthi Limited

Arun Kumar Bhangadia
Managing Director (DIN NO. 00021024)



Place : Hyderabad
Date : 28-06-2020

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)



Independent Auditor's Review Report on the Quarterly Unaudited Ind AS Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors
Trimurthi Limited

We have reviewed the accompanying statement of unaudited Ind AS standalone financial results of **TRIMURTHI LIMITED** (the "Company") for the quarter ended June 30, 2020 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ('Ind AS 34,') 'Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to give a report on "the Statement" based on our review.

We conducted our review of "the Statement" in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether "the Statement" is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying "Statement", prepared in accordance with the recognition and measurement principles laid down in the aforesaid "Ind AS 34" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.
Chartered Accountants
FRN: 007257S

A. Krishna Rao
Partner
M. No. 020085
UDIN:20020085AAAAJY5059



Place: Hyderabad
Date: 20-08-2020.

TRIMURTHI LIMITED
 SCHEDULE III OF THE COMPANIES ACT 2013
 CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2020



PART-I

TRIMURTHI
 GROUP

(Amounts in Rupees Except EPS)

Particulars	Quarter Ended			Year Ended
	30-06-2020	31-03-2020	30-06-2019	31-03-2020
	Unaudited	Audited	Unaudited	Audited
I. Income From Operations				
Net Sales / Income from Operations	205.47	266.24	243.68	1024.44
Other Income	11.81	21.30	4.24	60.11
II. Total Income	217.29	287.54	247.92	1084.55
III. Expenses				
a. Consumption of Raw Material	46.09	(9.27)	31.47	211.84
b. Purchase of Traded Goods/Shares	101.80	140.81	137.91	552.25
c. (Increase)/Decrease in stock in trade and work in Progress	(0.54)	(2.90)	(9.68)	(9.45)
d. Manufacturing Expenses	37.91	104.35	39.22	162.05
e. Employee benefits expense	22.55	23.04	22.24	96.49
f. Rent	1.40	2.25	1.50	6.75
g. Finance Cost	2.26	2.07	3.70	11.45
h. Depreciation	4.95	4.01	5.33	19.14
i. Other Expenditure	10.78	18.66	14.59	55.52
Total	227.20	283.02	246.30	1106.04
IV. Profit/(Loss) before Exceptional and Tax (II-III)	(9.92)	4.52	1.63	(21.50)
V. Exceptional Items/Prior Period Items				
VI. Profit/(Loss) before tax (IV-V)	(9.92)	4.52	1.63	(21.50)
VII. Tax expense:				
(1) Current tax	(0.96)	1.40	2.65	4.41
(2) Deferred tax	0.00	0.87	2.15	2.74
VIII. Net Profit/(Loss) for the period from continuing operations (VI-VII)	(8.95)	3.12	(1.03)	(25.91)
IX. Profit/(loss) from discontinued operations	-Nil-	-Nil-	-Nil-	-Nil-
X. Tax expenses of discontinued operations	-Nil-	-Nil-	-Nil-	-Nil-
XI. Profit/(loss) from Discontinued operations (after tax) (IX-X)	-Nil-	-Nil-	-Nil-	-Nil-
XII. Profit/(loss) for the period (VIII+XI)	(8.95)	3.12	(1.03)	(25.91)
XIII. Other Comprehensive Income				
A. (i) Items that will not be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-
B. (i) Items that will be reclassified to profit or loss	0.11	(2.01)	(1.90)	(3.43)
(ii) Income tax relating to items that will be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-
XIV. Total Comprehensive Income for the period (XII+XIII)Comprising Profit (Loss) and Other comprehensive Income for the period)	(8.85)	1.11	(2.93)	(29.34)
XV. Non Controlling Interest	(0.34)	0.26	1.12	2.43
XVI. Total Comprehensive Income for the period after Non controlling Interest (XIV-XV)	(8.50)	0.83	(4.05)	(31.76)
XVII. Earnings per equity share (for continuing operation):				
(1) Basic	(0.11)	0.04	(0.03)	(0.35)
(2) Diluted	(0.11)	0.04	(0.03)	(0.35)
XVIII. Earnings per equity share (for discontinuing operation):				
(1) Basic	-Nil-	-Nil-	-Nil-	-Nil-
(2) Diluted	-Nil-	-Nil-	-Nil-	-Nil-
XIX. Earnings per equity share (for discontinuing & continuing operation):				
(1) Basic	(0.11)	0.04	(0.03)	(0.35)
(2) Diluted	(0.11)	0.04	(0.03)	(0.35)

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)

TRIMURTHI LIMITED
SCHEDULE III OF THE COMPANIES ACT 2013

PART-II



TRIMURTHI

GROUP

PLC

LONDON

NEW YORK

SINGAPORE

SHANGHAI

CHENNAI

MUMBAI

BANGALORE

HYDERABAD

GOA

DELHI

KOLKATA

CHENNAI

MUMBAI

BANGALORE

HYDERABAD

GOA

Notes:

- 1 Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- 2 The Unaudited Consolidated Financial Results for the quarter ended June 30, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 20, 2020 and have been subjected to Limited Review by the Statutory Auditors of the Company. The Consolidated Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.
- 3 The results are also available on the website of the Company

Place : Hyderabad
Date : 20-08-2020

For Trimurthi Limited
Arun Kumar Bhangadia
Managing Director(DIN NO. 00021024)



TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)



Independent Auditor's Review Report on the Quarterly Unaudited Ind AS Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors
TRIMURTHI LIMITED

We have reviewed the accompanying unaudited Ind AS Consolidated financial results of **TRIMURTHI LIMITED** (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2020 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ("Ind AS 34"), 'Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on "the Statement" based on our review

We conducted our review of "the Statement" in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether "the Statement" is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

“The Statement” includes the Ind AS financial results of the following entities:

1. Trimurthi Foods Limited
2. Trimurthi Pharmaceuticals (India), Private Limited.

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.
Chartered Accountants
FRN: 007257S

A. Krishna Rao
Partner
M.No. 020085
UDIN:20020085AAAAJZ2113



Place: Hyderabad
Date: 20-08-2020.